Casualty Risk Trends: Pharmaceutical industry
Article information and share options
While pharmaceutical revenues are traditionally derived from a few products that are heavily marketed, decreasing R&D productivity together with pricing and reimbursement hurdles are driving change in the industry. The emergence of novel and advanced therapies is also creating new opportunities. Economic expansion and increasing affluence in the emerging markets are other factors driving growth in both prescription and over-the-counter drug markets.
These developments do not come without new risks. What can insurers do to minimise these? This Swiss Re Casualty Risk Trends report exemplifies the main questions related to the pharmaceutical industry and explains insurers what is important to bear in mind when insuring these risks.